Unlock instant, AI-driven research and patent intelligence for your innovation.
Method of treating progeria or progeria
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for progeria and a therapeutic agent, applied in the field of cell therapy, can solve problems such as progeria that have not yet been treated
Active Publication Date: 2019-09-20
BOYALIFE
View PDF5 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0091] Example 1: Treatment with placental mesenchymal stem cells, namely GD2+ stromal cells and umbilical cord blood KDR+ hematopoietic stem cells aging mice
[0092] 1. Selection and grouping of animals
[0093] 1. Selection of animals: Model mice are healthy C57BL / 6J mice, female, 8 weeks old, weighing 18-22 g, 60 mice.
[0094] 2. Grouping of animals: Simply randomly divide them into three groups: control group, model group and treatment group, with 20 animals in each group.
[0095] 2. Establishment of mouse aging model
[0096] The model group and the treatment group were subcutaneously injected with 5% D-galactose on the back of the neck every day, the injection volume was 0.25ml / 10g, and the aging animal model was established by continuous administration for 8-16 weeks. The control group was given the same volume of normal saline.
[0097] 3. Infusion
[0098] Two weeks after the aging model was established, the treatment group was injected with GD2+ placental M...
Embodiment 2
[0114] Example 2: Treatment with placental mesenchymal stem cells, namely GD2+ stromal cells and umbilical cord blood KDR+ hematopoietic stem cells aging mice
[0115] In Example 2 and its supplementary tests, if not otherwise stated, glycine and mannitol were added to the mesenchymal stem cell suspension used.
[0116] 1. Selection and grouping of animals
[0117] 1. Selection of animals: Model mice are healthy C57BL / 6J mice, female, 8 weeks old, weighing 18-22 g, 60 mice.
[0118] 2. Grouping of animals: Simply randomly divide them into three groups: control group, model group and treatment group, with 20 animals in each group.
[0119] 2. Establishment of mouse aging model
[0120] The model group and the treatment group were subcutaneously injected with 5% D-galactose on the back of the neck every day, the injection volume was 0.25ml / 10g, and the aging animal model was established by continuous administration for 8-16 weeks. The control group was given the same volu...
Embodiment 3
[0140] Example 3: Mechanism research on MSC+HSC treatment of aging mice
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the technical field of cell treating, relates to a method for treating progeria or Hutchinson-Gilford progeria syndrome, in particular to a treating agent for restoring body function aging and delaying recession of organ functions and comprising GD2+ stroma cells and KDR+ hematopoietic stem cells and further relates to application, in preparation of the treating agent for treating progeria or Hutchinson-Gilford progeria syndrome or for restoring body function aging and delaying recession of the organ functions, of the combination of the GD2+ stroma cells and the KDR+ hematopoietic stem cells. It has been found that the treating agent can be effectively used for treating progeria or Hutchinson-Gilford progeria syndrome, especially for restoring body function aging and delaying recession of the organ functions.
Description
technical field [0001] The invention belongs to the technical field of cell therapy, and relates to a method for treating progeria or progeria, in particular to a therapeutic agent for repairing the aging of body functions and delaying the decline of organ functions, in particular to a method comprising GD2+ stromal cells and therapeutic agents for KDR+ hematopoietic stem cells. Further, the present invention relates to the use of the combination of GD2+ stromal cells and KDR+ hematopoietic stem cells in the preparation of therapeutic agents for treating progeria or progeria or for repairing aging of body functions and delaying organ function decline. It has been found that the therapeutic agent of the present invention can be effectively used for the treatment of progeria or progeria, especially for repairing the aging of body functions and delaying the decline of organ functions. Background technique [0002] Aging can be divided into physiological aging and pathological ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More